Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Autor:	Harbeck, Nadia, Wrobel, Denise, Zaiss, Matthias, Terhaag, Jürgen, Guth, Dagmar, Distelrath, Andrea, Zahn, Mark-Oliver, Würstlein, Rachel, Lorenz, Andreas, Bartsch, Rupert, Breitenstein, Urs, Schwitter, Michael, Balic, Marija, Jackisch, Christian, Müller, Volkmar, Rinnerthaler, Gabriel, Schmidt, Marcus, Zaman, Khalil, Schinköthe, Timo, Resch, Anna
Předmět:	THERAPEUTIC use of antineoplastic agents ADJUVANT chemotherapy DRUG efficacy RESEARCH CLINICAL trials EPIDERMAL growth factor receptors ANTINEOPLASTIC agents PROTEIN-tyrosine kinase inhibitors DRUGS DESCRIPTIVE statistics RESEARCH funding PATIENT compliance HORMONE receptor positive breast cancer BREAST tumors LONGITUDINAL method EVALUATION
Zdroj:	Breast Care; 2024, Vol. 19 Issue 1, p1-9, 8p
Abstrakt:	Introduction: Prognosis of patients diagnosed with HER2+ early breast cancer (eBC) has substantially improved, but distant recurrences impacting quality of life and survival still occur. One treatment option for extended adjuvant treatment of patients with HER2+/HR+ eBC is neratinib, available in Europe for patients who completed adjuvant trastuzumab-based therapy within 1 year. The ELEANOR study is investigating the real-world use of neratinib in Germany, Austria, and Switzerland. Results from an interim analysis of the first 200 patients observed for ≥3 months are reported. Methods: The primary objective of this prospective, multicenter, observational study is to assess patient adherence to neratinib (defined as the percentage of patients taking neratinib on ≥75% prescribed days). Secondary objectives are patient characteristics and treatment outcomes. Results: At cut-off (May 2, 2022), a total of 202 patients had been observed for ≥3 months, with neratinib treatment documented for 187 patients (median age: 53.0 years; 67.9% at increased risk of disease recurrence). In total, 151 (80.7%) patients had received prior neoadjuvant treatment; of these, 82 (54.3%) patients achieved a pathologically complete response. Neratinib was initiated at a median 3.6 months after trastuzumab-based treatment, with 36.4% starting at a dose <240 mg/day. Treatment is ongoing for 46.0% of patients, with median treatment duration of 11.2 (interquartile range 0.9–12.0) months. Diarrhea was the most common adverse event (78.6% any grade, 20.3% grade ≥3); pharmacologic prophylaxis was used in 85.6% of patients. Conclusions: The pattern of anti-HER2 pretreatment observed reflected the current treatment for HER2+/HR+ eBC in Germany, Austria, and Switzerland. These interim results suggest that neratinib as an extended adjuvant is a feasible option after various anti-HER2 pretreatments and that its tolerability can be managed and improved with proactive diarrhea management. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu